174 related articles for article (PubMed ID: 34465864)
21. LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.
Cheng Y; Chikwava K; Wu C; Zhang H; Bhagat A; Pei D; Choi JK; Tong W
J Clin Invest; 2016 Apr; 126(4):1267-81. PubMed ID: 26974155
[TBL] [Abstract][Full Text] [Related]
22. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.
Bergmann AK; Schneppenheim S; Seifert M; Betts MJ; Haake A; Lopez C; Maria Murga Penas E; Vater I; Jayne S; Dyer MJ; Schrappe M; Dührsen U; Ammerpohl O; Russell RB; Küppers R; Dürig J; Siebert R
Genes Chromosomes Cancer; 2014 Apr; 53(4):309-16. PubMed ID: 24446122
[TBL] [Abstract][Full Text] [Related]
23. Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.
Sim SH; Kim S; Kim TM; Jeon YK; Nam SJ; Ahn YO; Keam B; Park HH; Kim DW; Kim CW; Heo DS
Am J Pathol; 2017 May; 187(5):980-986. PubMed ID: 28284718
[TBL] [Abstract][Full Text] [Related]
24. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
Kirken RA; Erwin RA; Wang L; Wang Y; Rui H; Farrar WL
J Immunol; 2000 Nov; 165(9):5097-104. PubMed ID: 11046040
[TBL] [Abstract][Full Text] [Related]
25. Somatic mutation of PHF6 gene in T-cell acute lymphoblatic leukemia, acute myelogenous leukemia and hepatocellular carcinoma.
Yoo NJ; Kim YR; Lee SH
Acta Oncol; 2012 Jan; 51(1):107-11. PubMed ID: 21736506
[TBL] [Abstract][Full Text] [Related]
26. Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.
Ehrentraut S; Schneider B; Nagel S; Pommerenke C; Quentmeier H; Geffers R; Feist M; Kaufmann M; Meyer C; Kadin ME; Drexler HG; MacLeod RA
Oncotarget; 2016 Jun; 7(23):34201-16. PubMed ID: 27144517
[TBL] [Abstract][Full Text] [Related]
27. The Role of PHF6 in Hematopoiesis and Hematologic Malignancies.
Eisa YA; Guo Y; Yang FC
Stem Cell Rev Rep; 2023 Jan; 19(1):67-75. PubMed ID: 36008597
[TBL] [Abstract][Full Text] [Related]
28. Phf6-null hematopoietic stem cells have enhanced self-renewal capacity and oncogenic potentials.
Hsu YC; Chen TC; Lin CC; Yuan CT; Hsu CL; Hou HA; Kao CJ; Chuang PH; Chen YR; Chou WC; Tien HF
Blood Adv; 2019 Aug; 3(15):2355-2367. PubMed ID: 31395598
[No Abstract] [Full Text] [Related]
29. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors.
Springuel L; Hornakova T; Losdyck E; Lambert F; Leroy E; Constantinescu SN; Flex E; Tartaglia M; Knoops L; Renauld JC
Blood; 2014 Dec; 124(26):3924-31. PubMed ID: 25352124
[TBL] [Abstract][Full Text] [Related]
30. Structural and functional insights into the human Börjeson-Forssman-Lehmann syndrome-associated protein PHF6.
Liu Z; Li F; Ruan K; Zhang J; Mei Y; Wu J; Shi Y
J Biol Chem; 2014 Apr; 289(14):10069-83. PubMed ID: 24554700
[TBL] [Abstract][Full Text] [Related]
31. T-cell acute lymphoblastic leukemia in association with Börjeson-Forssman-Lehmann syndrome due to a mutation in PHF6.
Chao MM; Todd MA; Kontny U; Neas K; Sullivan MJ; Hunter AG; Picketts DJ; Kratz CP
Pediatr Blood Cancer; 2010 Oct; 55(4):722-4. PubMed ID: 20806366
[TBL] [Abstract][Full Text] [Related]
32. Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene.
Zhang LL; Pan HX; Wang YX; Guo T; Liu L
Int J Oncol; 2019 Nov; 55(5):1077-1089. PubMed ID: 31545408
[TBL] [Abstract][Full Text] [Related]
33. PHF6 loss reduces leukemia stem cell activity in an acute myeloid leukemia mouse model.
Yuan S; Gao M; Wang Y; Lan Y; Li M; Du Y; Li Y; Ju W; Huang Y; Yuan K; Zeng L
Cancer Cell Int; 2024 Feb; 24(1):66. PubMed ID: 38336746
[TBL] [Abstract][Full Text] [Related]
34. Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.
Lim M; Batista CR; de Oliveira BR; Creighton R; Ferguson J; Clemmer K; Knight D; Iansavitchous J; Mahmood D; Avino M; DeKoter RP
Mol Cell Biol; 2020 Aug; 40(18):. PubMed ID: 32631903
[TBL] [Abstract][Full Text] [Related]
35. N-Acetylcysteine Alters Disease Progression and Increases Janus Kinase Mutation Frequency in a Mouse Model of Precursor B-Cell Acute Lymphoblastic Leukemia.
Sams MP; Iansavitchous J; Astridge M; Rysan H; Xu LS; Rodrigues de Oliveira B; DeKoter RP
J Pharmacol Exp Ther; 2024 Mar; 389(1):40-50. PubMed ID: 38336380
[TBL] [Abstract][Full Text] [Related]
36. In vivo impact of JAK3 A573V mutation revealed using zebrafish.
Basheer F; Bulleeraz V; Ngo VQT; Liongue C; Ward AC
Cell Mol Life Sci; 2022 May; 79(6):322. PubMed ID: 35622134
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
Zenatti PP; Ribeiro D; Li W; Zuurbier L; Silva MC; Paganin M; Tritapoe J; Hixon JA; Silveira AB; Cardoso BA; Sarmento LM; Correia N; Toribio ML; Kobarg J; Horstmann M; Pieters R; Brandalise SR; Ferrando AA; Meijerink JP; Durum SK; Yunes JA; Barata JT
Nat Genet; 2011 Sep; 43(10):932-9. PubMed ID: 21892159
[TBL] [Abstract][Full Text] [Related]
38. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.
Hornakova T; Staerk J; Royer Y; Flex E; Tartaglia M; Constantinescu SN; Knoops L; Renauld JC
J Biol Chem; 2009 Mar; 284(11):6773-81. PubMed ID: 19139102
[TBL] [Abstract][Full Text] [Related]
39. SIRT1 regulates the phosphorylation and degradation of P27 by deacetylating CDK2 to promote T-cell acute lymphoblastic leukemia progression.
Wang F; Li Z; Zhou J; Wang G; Zhang W; Xu J; Liang A
J Exp Clin Cancer Res; 2021 Aug; 40(1):259. PubMed ID: 34407842
[TBL] [Abstract][Full Text] [Related]
40. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.
Bains T; Heinrich MC; Loriaux MM; Beadling C; Nelson D; Warrick A; Neff TL; Tyner JW; Dunlap J; Corless CL; Fan G
Leukemia; 2012 Sep; 26(9):2144-6. PubMed ID: 22425895
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
